Brain Cancer Clinical Trials

Brain: Treatment Trials 

Study Title: A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Brain: Symptom Management & Quality of Life

Study Title: UVMCC 1702: Venous thromboembolism (VTE) prevention in patients with malignant glioma
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: MSKCC 15-034 GBM Coping: Coping with glioblastoma: A study of communication between physicians, patients, and caregivers
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: UVMCC 1603: Fatigue in Patients with Primary Brain Tumors
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Breast Cancer Clinical Trials

Breast: Treatment Trials 

Study Title: NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: NSABP B-55:  A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: VCC 0601 – Phase I/II Trial to Evaluate Partial Breast Radiation to the Region of the Lumpectomy Cavity Using Intensity Modulated Radiation Therapy (IMRT) in Elderly Women with Breast Cancer
Primary/Site/Co Investigator: Ruth Heimann, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A011106 – ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: S1207:  Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year  of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Primary/Site/Co Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Primary/Site/Co Investigator: Michelle Sowden, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A011502: A Randomized Phase III Double Blind Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: AFT25 COMET: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

 Breast: Symptom Management & Quality of Life Trials

Study Title: Alternative exercise program to improve skeletal muscle function and fatigue in cancer survivors
Primary/Site/Co-Investigator: Michael Toth, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A221405 POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy (POSITIVE)
Primary/Site/Co-Investigator: Kim Dittus, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

 Colon Cancer Clinical Trials

Colon: Treatment Trials

Study Title: S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Primary/Site/Co-Investigator: Krista Evans, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Esophageal Cancer Clinical Trials

Esophageal: Symptom Management & Quality of Life

Study Title: UVMCC 1606: Quality of Life Assessment for Head and Neck Cancer Patients Undergoing Treatment in the First Year of Survivorship
Primary/Site/Co-Investigator: Maura Barry, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Hematologic Malignancy Cancer Clinical Trials

Hematologic Malignancy: Treatment Trials 

Study Title: PCYC-1145-LT: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Primary/Site/Co-Investigator: Julian Sprague, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Kidney Cancer Clinical Trials

Kidney: Treatment Trials

Study Title: EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Primary/Site/Co-Investigator: Scott Perrapato, DO, FACOS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung Cancer Clinical Trials

Lung: Treatment Trials

Study Title: SWOG 1400: Phase II/III Biomarker Driven Master Protocol for Second-Line Therapy of Squamous Cell Lung Cancer
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) 
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: ECOG EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Lung: Symptom Management & Quality of Life

Study Title: A211401: Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Primary/Site/Co Investigator: Garth Garrison, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
 

Melanoma Clinical Trials

Melanoma: Treatment Trials 

Study Title: ECOG EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Myeloma Clinical Trials

Myeloma: Treatment Trials 

Study Title: E1A11 (ENDURANCE): Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus CarfAlzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma
Primary/Site/Co-Investigator: Julian Sprague, MD, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Multiple Cancer Sites Clinical Trials

Multiple Cancer Sites: Treatment Trials 

Study Title: A8081001: Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer
Primary/Site/Co-Investigator: Steven Ades, MD, MSc
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: EAY131 (MATCH): Molecular Analysis for Therapy Choice (MATCH), Master Protocol 
Primary/Site/Co-Investigator: Marc Greenblatt, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: AFT28 CANVAS: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A randomized Effectiveness Trial (CANVAS trial)
Primary/Site/Co Investigator: Chris Holmes, MD, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Multiple Cancer Sites: Symptom Management & Quality of Life

Study Title: UVMCC 1518 (VTE-PACC): VTE Prophylaxis in the Ambulatory Cancer Clinic (VTE-PACC)
Primary/Site/Co-Investigator: Chris Holmes, MD, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
 
Study Title: VCC 1107: Oncology Rehabilitation Database
Primary/Site/Co-Investigator: Kim Dittus, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2

Ovarian Cancer Clinical Trials

Ovarian: Treatment Trials 

Study Title: NRG GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Primary/Site/Co-Investigator: Cheung Wong, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Prostate Cancer Clinical Trials

Prostate: Treatment Trials

 
Study Title: NRG GU006: A phase II, double-blinded placebo controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer
Primary/Site/Co-Investigator: James Wallace, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: NRG GU005: Phase III Image-Guided RadiationTherapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT) vs. IGRT and Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) for localized intermediate risk prostate cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate and Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
Primary/Site/Co-Investigator: H. James Wallace III, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Rectum Cancer Clinical Trials

Rectum: Treatment Trials

Study Title: S0820:A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Primary/Site/Co-Investigator: Krista Evans, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: Alliance Trial PROSPECT N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Res
Primary/Site/Co-Investigator: Steven Ades, MD, MSc
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: MSKCC 13213: A phase II multicenter randomized trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or non-operative manage
Primary/Site/Co-Investigator: Peter Cataldo, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: NRG GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Primary/Site/Co-Investigator: Christopher Anker, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Primary/Site/Co-Investigator: Maura Barry, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Sarcoma and Soft Tissue Cancer Clinical Trials

Sarcoma: Treatment Trials 

Study Title: A091304: A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma
Primary/Site/Co-Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

Other Ways to Help Advance Cancer Research

Breast Study Title: UVMCC 1706: Effect of anti-inflammatory treatment on local immune response triggered by breast tumor biopsy
Primary/Site/Co-Investigator: James East, MD, PhD and Mercedes Rincon, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: UVMCC 1515: Assessment of intrinsic fluorescence as a diagnostic tool for breast cancer tumors and nodal involvement
Primary/Site/Co Investigator: Gary Stein, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: VCC 1106: Tumor Binding Antibodies from Cancer Patients
Primary/Site/Co Investigator: David Krag, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Study Title: V0806: Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients with Cancer
Primary/Site/Co Investigator: Chris Holmes, MD, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2 or Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast & Ovarian Study Title: V0308:  Clinical and Molecular Markers of Risk for Breast and Ovarian Cancers
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: UVMCC 1704: The DNA Repair Landscape of Women at Risk for Breast Cancer: Family Studies Companion
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Breast Study Title: VCC 1205: The DNA Repair Landscape of Women at Risk for Breast Cancer
Primary/Site/Co Investigator: Marie Wood, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2
To Learn More or Enroll: Call (802)656-4414 ext. 2
Lung Study Title: A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2 or Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2
Brain Study Title: D12160: Evaluating the Expression Levels of microRNA-10b in Patients with Gliomas
Primary/Site/Co Investigator: Alissa Thomas, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802)656-4414 ext. 2 or Click Here
To Learn More or Enroll: Call (802)656-4414 ext. 2

About Us

FAQs

Contact Us

Trials by Cancer Type

Click below to view open cancer trials by type. 

BrainBreast ColonEsophagealHematologic MalignancyKidneyLungMelanomaMyelomaMultiple SitesOvarianPediatric ProstateRectumSarcoma and Soft TissueOther Ways to Help Advance Cancer Research

Enroll Now

If you have any questions or would like to enroll in one of these clinical trials, please call (802) 656-4414 ext. 2.